

Description of Additional Supplementary Files

File Name: Supplementary Data 1

Description: INSPIRE patient cancer type, clinical outcome, and data availability.

File Name: Supplementary Data 2

Description: Mutation enrichment in baseline tumors with high and low pembrolizumab molecular sensitivity.

File Name: Supplementary Data 3

Description: Differentially expressed genes after anti-PD1 treatment in HS/CB tumors.

File Name: Supplementary Data 4

Description: Differentially expressed genes after anti-PD1 treatment in LS tumors.

File Name: Supplementary Data 5

Description: Differentially regulated genes between HS/CB and LS tumors.

File Name: Supplementary Data 6

Description: GO biological processes terms enriched in selected DRGs.